The goal of the Mayo Clinic Center for Cell Signaling in Gastroenterology (C-SiG) is to connect discovery, translational, and patient-oriented investigators to enhance understanding and therapeutically exploit signaling pathways in gastrointestinal cells to improve the health of patients with digestive diseases. The Research Base consists of 59 scientists and $23 million (direct costs, 70% growth) in digestive disease related funding. C-SiG members are organized into three Mechanistic Research Themes: 1) Ion channels/membrane receptors;ii) Signal transduction;and, iii) Genetics and gene regulation. Our CENTRAL HYPOTHESIS is that advances in clinical care of patients with digestive diseases requires a facilitative infrastructure supporting meaningful interactions among multidisciplinary scientists investigating cellular mechanisms, pathways and therapeutic targets to enhance rapid translation of basic discoveries into clinical trials. C-SiG's OVERALL SPECIFIC AIMS are to: i) Foster multidisciplinary research by expanding technical and collaborative capabilities of established Gl scientists and attracting investigators from other disciplines;li) Develop and implement a robust Scientific Enrichment Program that includes seminars, workshops, symposia, a visiting faculty program, minisabbatical, and Web-based curricula;iii) Offer specialized equipment, technologies, methodologies, reagents, and expertise to assist C-SiG members through the C-SiG Cores, including: a) State-of-the-art microscopic technology and consultative expertise (Optical Microscopy Core);b) Accelerated and expanded biospecimen acquisition, processing, and annotation (Clinical Core);c) Emerging genetic technologies and model systems (Genetics and Model Systems Core);iv) Identify and nurture new Gl investigators via a peer-reviewed Pilot and Feasibility Program;v) Promote synergistic interactions between C-SiG members and other Gl investigators at Mayo and at other Gl centers to facilitate clinical trials resulting from the identification of cellular therapeutic tarets;vi) Share technologies with other NIDDK centers at Mayo (e.g., PKD Center) and existing Digestive Disease Research Core Centers, especially in the Midwest (i.e. Midwest DDRCC Alliance).

Public Health Relevance

Gastrointestinal diseases and their complications have a significant effect on public health and health care utilization costs. Research supported by this Center grant, is critically important for furthering understanding of the mechanisms that underlie digestive diseases, which can lead to practical applications for the diagnosis, prevention, monitoring and treatment of human disease

Agency
National Institute of Health (NIH)
Type
Center Core Grants (P30)
Project #
2P30DK084567-06
Application #
8699451
Study Section
Special Emphasis Panel (ZDK1)
Program Officer
Grey, Michael J
Project Start
Project End
Budget Start
Budget End
Support Year
6
Fiscal Year
2014
Total Cost
Indirect Cost
Name
Mayo Clinic, Rochester
Department
Type
DUNS #
City
Rochester
State
MN
Country
United States
Zip Code
55905
Ni, Jun; Wangensteen, Kirk J; Nelsen, David et al. (2016) Active recombinant Tol2 transposase for gene transfer and gene discovery applications. Mob DNA 7:6
Landry, Greg M; Hirata, Taku; Anderson, Jacob B et al. (2016) Sulfate and thiosulfate inhibit oxalate transport via a dPrestin (Slc26a6)-dependent mechanism in an insect model of calcium oxalate nephrolithiasis. Am J Physiol Renal Physiol 310:F152-9
Ma, Alvin C; McNulty, Melissa S; Poshusta, Tanya L et al. (2016) FusX: A Rapid One-Step Transcription Activator-Like Effector Assembly System for Genome Science. Hum Gene Ther 27:451-63
Khanna, S; Montassier, E; Schmidt, B et al. (2016) Gut microbiome predictors of treatment response and recurrence in primary Clostridium difficile infection. Aliment Pharmacol Ther 44:715-27
Druliner, Brooke R; Rashtak, Shahrooz; Ruan, Xiaoyang et al. (2016) Colorectal Cancer with Residual Polyp of Origin: A Model of Malignant Transformation. Transl Oncol 9:280-6
Tomita, Kyoko; Freeman, Brittany L; Bronk, Steven F et al. (2016) CXCL10-Mediates Macrophage, but not Other Innate Immune Cells-Associated Inflammation in Murine Nonalcoholic Steatohepatitis. Sci Rep 6:28786
Kawakami, Hisato; Huang, Shengbing; Pal, Krishnendu et al. (2016) Mutant BRAF Upregulates MCL-1 to Confer Apoptosis Resistance that Is Reversed by MCL-1 Antagonism and Cobimetinib in Colorectal Cancer. Mol Cancer Ther 15:3015-3027
Tabibian, James H; Varghese, Cyril; LaRusso, Nicholas F et al. (2016) The enteric microbiome in hepatobiliary health and disease. Liver Int 36:480-7
Verma, Vikas K; Li, Haiyang; Wang, Ruisi et al. (2016) Alcohol stimulates macrophage activation through caspase-dependent hepatocyte derived release of CD40L containing extracellular vesicles. J Hepatol 64:651-60
Ding, Xiwei; Chaiteerakij, Roongruedee; Moser, Catherine D et al. (2016) Antitumor effect of the novel sphingosine kinase 2 inhibitor ABC294640 is enhanced by inhibition of autophagy and by sorafenib in human cholangiocarcinoma cells. Oncotarget 7:20080-92

Showing the most recent 10 out of 399 publications